Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 13/20 | 0.60 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16660881 | 0.87 | DGAT1 (0.46) | DGAT1KDM4EALDH1A1HSD17B10CYP2C9 | |
| SCHEMBL374769 | 0.84 | DGAT1 (0.58) | DGAT1KDM4EALDH1A1L3MBTL1RAB9A | |
| SCHEMBL20730072 | 0.81 | DGAT1 (0.56) | DGAT1KDM4EL3MBTL1 | |
| SCHEMBL23309220 | 0.80 | DGAT1 (0.55) | DGAT1L3MBTL1 | |
| SCHEMBL10007447 | 0.79 | DGAT1 (0.60) | DGAT1 | |
| Potassium Ion SCHEMBL374697 | 0.79 | DGAT1 (0.54) | DGAT1L3MBTL1 | |
| SCHEMBL18541134 | 0.78 | DGAT1 (0.62) | DGAT1L3MBTL1RAB9A | |
| SCHEMBL16661033 | 0.78 | DGAT1 (0.62) | DGAT1L3MBTL1MAPT | |
| SCHEMBL23309284 | 0.78 | DGAT1 (0.53) | DGAT1KDM4EALDH1A1L3MBTL1MAPT | |
| SCHEMBL13948727 | 0.78 | CYP2C9 (0.46) | DGAT1ALDH1A1CYP2C9L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365192-B2 | Pyridine compound substituted with azole | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-21 | — | — | US | disclosed |
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2021-04-29 | — | — | US | disclosed |
| EP-3666766-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | Taisho Pharmaceutical Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| EP-2651915-B1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-25 | — | — | EP | disclosed |
| WO-2012024179-A1 | SUBSTITUTED AMIDE DERIVATIVES AS DGAT-1 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | CYP2C19, CYP4A11, CYP11B1 | DGAT1 1601/4885P2RX3 1873/4885KDM4E 169/4885 |
| US-11365192-B2 | Pyridine compound substituted with azole | CYP2C19, CYP4A11, CYP11B1 | DGAT1 1601/4885P2RX3 1873/4885KDM4E 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.